{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:59:34Z","timestamp":1762459174991},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,4,13]],"date-time":"2014-04-13T00:00:00Z","timestamp":1397347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s00393-013-1286-7","type":"journal-article","created":{"date-parts":[[2014,4,11]],"date-time":"2014-04-11T20:40:57Z","timestamp":1397248857000},"page":"323-328","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmakogene Osteoporose jenseits von Kortison"],"prefix":"10.1007","volume":"73","author":[{"given":"P.H.","family":"Kann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Hadji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.S.","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,13]]},"reference":[{"key":"1286_CR1","unstructured":"oA (2013) EMA und FDA untersuchen Pankreasrisiken von GLP-1-basierten Therapien. Deutsches \u00c4rzteblatt. http:\/\/www.aerzteblatt.de\/nachrichten\/53869\/EMA-und-FDA-untersuchen-Pankreasrisiken-von-GLP-1-basierten-Therapien. Zugegriffen: 31.03.2014"},{"key":"1286_CR2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.maturitas.2013.02.007","volume":"75","author":"Arampatzis","year":"2013","unstructured":"Arampatzis S, Gaetcke LM, Funk GC et al (2013) Diuretic-induced hyponatremia and osteoporotic fractures in patients admitted to the emergency department. Maturitas 75:81\u201386","journal-title":"Maturitas"},{"key":"1286_CR3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.trsl.2012.08.006","volume":"161","author":"Beck","year":"2013","unstructured":"Beck GR Jr, Khazai NB, Bouloux GF et al (2013) The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes. Transl Res 161:145\u2013155","journal-title":"Transl Res"},{"key":"1286_CR4","first-page":"305","volume":"Endocrinol","author":"Berberoglu","year":"2010","unstructured":"Berberoglu Z, Yazici AC, Demirag NG (2010) Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study. Clin Endocrinol (Oxf) 73:305\u2013312","journal-title":"Clin"},{"key":"1286_CR5","unstructured":"Berry et al. (2013)"},{"key":"1286_CR6","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1210\/jc.2012-4096","volume":"98","author":"Bone","year":"2013","unstructured":"Bone HG, Lindsay R, McClung MR et al (2013) Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 98:4691\u20134701","journal-title":"J Clin Endocrinol Metab"},{"key":"1286_CR7","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.2337\/dc12-2713","volume":"36","author":"Butler","year":"2013","unstructured":"Butler PC, Elashoff M, Elashoff R, Gale EA (2013) A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 36:2118\u20132125","journal-title":"Diabetes Care"},{"key":"1286_CR8","doi-asserted-by":"crossref","first-page":"666","DOI":"10.7326\/0003-4819-118-9-199305010-00002","volume":"118","author":"Cauley","year":"1993","unstructured":"Cauley JA, Cummings SR, Seeley DG et al (1993) Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The Study of Osteoporotic Fractures Research Group. Ann Intern Med 118:666\u2013673","journal-title":"Ann Intern Med"},{"key":"1286_CR9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1053\/j.gastro.2010.03.055","volume":"139","author":"Corley","year":"2010","unstructured":"Corley DA, Kubo A, Zhao W, Quesenberry C (2010) Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 139:93\u2013101","journal-title":"Gastroenterology"},{"key":"1286_CR10","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1681\/ASN.2007030348","volume":"18","author":"Dvorak","year":"2007","unstructured":"Dvorak MM, De Joussineau C, Carter DH et al (2007) Thiazide diuretics directly induce osteoblast differentiation and mineralized nodule formation by interacting with a sodium chloride co-transporter in bone. J Am Soc Nephrol 18:2509\u20132516","journal-title":"J Am Soc Nephrol"},{"key":"1286_CR11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF01623465","volume":"7","author":"Feskanich","year":"1997","unstructured":"Feskanich D, Willett WC, Stampfer MJ, Colditz GA (1997) A prospective study of thiazide use and fractures in women. Osteoporos Int 7:79\u201384","journal-title":"Osteoporos Int"},{"key":"1286_CR12","doi-asserted-by":"crossref","first-page":"52950","DOI":"10.1155\/PPAR\/2006\/52950","volume":"2006","author":"Floyd","year":"2006","unstructured":"Floyd ZE, Zvonic S, E Nuttall M, M Gimble J (2006) Fine-tuning reception in the bone: PPARgamma and company. PPAR Res 2006:52950","journal-title":"PPAR Res"},{"key":"1286_CR13","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00198-012-2112-9","volume":"24","author":"Fraser","year":"2013","unstructured":"Fraser LA, Leslie WD, Targownik LE et al (2013) The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int 24:1161\u20131168","journal-title":"Osteoporos Int"},{"key":"1286_CR14","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1210\/jc.2007-2249","volume":"93","author":"Glintborg","year":"2008","unstructured":"Glintborg D, Andersen M, Hagen C et al (2008) Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 93:1696\u20131701","journal-title":"J Clin Endocrinol Metab"},{"key":"1286_CR15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00223-010-9392-x","volume":"87","author":"Gonnelli","year":"2010","unstructured":"Gonnelli S, Caffarelli C, Maggi S et al (2010) Effect of inhaled glucocorticoids and beta(2) agonists on vertebral fracture risk in COPD patients: the EOLO study. Calcif Tissue Int 87:137\u2013143","journal-title":"Calcif Tissue Int"},{"key":"1286_CR16","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/archinternmed.2010.94","volume":"170","author":"Gray","year":"2010","unstructured":"Gray SL, LaCroix AZ, Larson J et al (2010) Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women\u2019s Health Initiative. Arch Intern Med 170:765\u2013771","journal-title":"Arch Intern Med"},{"key":"1286_CR17","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2006-2646","volume":"92","author":"Grey","year":"2007","unstructured":"Grey A, Bolland M, Gamble G et al (2007) The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92:1305\u20131310","journal-title":"J Clin Endocrinol Metab"},{"key":"1286_CR18","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/oxfordjournals.aje.a009171","volume":"145","author":"Grisso","year":"1997","unstructured":"Grisso JA, Kelsey JL, O\u2019Brien LA et al (1997) Risk factors for hip fracture in men. Hip Fracture Study Group. Am J Epidemiol 145:786\u2013793","journal-title":"Am J Epidemiol"},{"key":"1286_CR19","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1002\/jbmr.166","volume":"25","author":"Hansen","year":"2010","unstructured":"Hansen KE, Jones AN, Lindstrom MJ et al (2010) Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res 25:2786\u20132795","journal-title":"J Bone Miner Res"},{"key":"1286_CR20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00223-012-9671-9","volume":"92","author":"Ili\u0107","year":"2013","unstructured":"Ili\u0107 K, Obradovi\u0107 N, Vujasinovi\u0107-Stupar N (2013) The relationship among hypertension, antihypertensive medications, and osteoporosis: a narrative review. Calcif Tissue Int 92:217\u2013227","journal-title":"Calcif Tissue Int"},{"key":"1286_CR21","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"Kahn","year":"2006","unstructured":"Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427\u20132443","journal-title":"N Engl J Med"},{"key":"1286_CR22","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1056\/NEJM199002013220502","volume":"322","author":"LaCroix","year":"1990","unstructured":"LaCroix AZ, Wienpahl J, White LR et al (1990) Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med 322:286\u2013290","journal-title":"N Engl J Med"},{"key":"1286_CR23","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1038\/ajg.2009.48","volume":"104","author":"Laine","year":"2009","unstructured":"Laine L (2009) Proton pump inhibitors and bone fractures? Am J Gastroenterol 104(Suppl 2):S21\u2013S26","journal-title":"Am J Gastroenterol"},{"key":"1286_CR24","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1161\/01.CIR.0000165072.01672.21","volume":"111","author":"Langenfeld","year":"2005","unstructured":"Langenfeld MR, Forst T, Hohberg C et al (2005) Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 111:2525\u20132531","journal-title":"Circulation"},{"key":"1286_CR25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0961203309353171","volume":"19","author":"Lefkou","year":"2010","unstructured":"Lefkou E, Khamashta M, Hampson G, Hunt BJ (2010) Review: low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: a myth or an existing entity? Lupus 19:3\u201312","journal-title":"Lupus"},{"key":"1286_CR26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bone.2003.08.007","volume":"34","author":"Lesclous","year":"2004","unstructured":"Lesclous P, Guez D, Baroukh B et al (2004) Histamine participates in the early phase of trabecular bone loss in ovariectomized rats. Bone 34:91\u201399","journal-title":"Bone"},{"key":"1286_CR27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S8756-3282(01)00629-9","volume":"30","author":"Lesclous","year":"2002","unstructured":"Lesclous P, Guez D, Saffar JL (2002) Short-term prevention of osteoclastic resorption and osteopenia in ovariectomized rats treated with the H(2) receptor antagonist cimetidine. Bone 30:131\u2013136","journal-title":"Bone"},{"key":"1286_CR28","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/archinte.168.7.735","volume":"168","author":"Lim","year":"2008","unstructured":"Lim LS, Fink HA, Kuskowski MA et al (2008) Loop diuretic use and increased rates of hip bone loss in older men: the Osteoporotic Fractures in Men Study. Arch Intern Med 168:735\u2013740","journal-title":"Arch Intern Med"},{"key":"1286_CR29","doi-asserted-by":"crossref","first-page":"64807","DOI":"10.1155\/PPAR\/2006\/64807","volume":"2006","author":"Marie","year":"2006","unstructured":"Marie PJ, Kaabeche K (2006) PPAR gamma activity and control of bone mass in skeletal unloading. PPAR Res 2006:64807","journal-title":"PPAR Res"},{"key":"1286_CR30","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archinte.168.8.820","volume":"168","author":"Meier","year":"2008","unstructured":"Meier C, Kraenzlin ME, Bodmer M et al (2008) Use of thiazolidinediones and fracture risk. Arch Intern Med 168:820\u2013825","journal-title":"Arch Intern Med"},{"key":"1286_CR31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF01352010","volume":"53","author":"Mizunashi","year":"1993","unstructured":"Mizunashi K, Furukawa Y, Katano K, Abe K (1993) Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 53:21\u201325","journal-title":"Calcif Tissue Int"},{"key":"1286_CR32","unstructured":"Overbeck P (2013) EMA gibt Entwarnung. \u00c4rzte Zeitung online. www.aerztezeitung.de\/medizin\/krankheiten\/diabetes\/article\/843404\/glp-1-therapien-ema-gibt-entwarnung.html. Zugegriffen: 31.03.2014"},{"key":"1286_CR33","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(89)92205-8","volume":"1","author":"Ray","year":"1989","unstructured":"Ray WA, Griffin MR, Downey W, Melton LJ III (1989) Long-term use of thiazide diuretics and risk of hip fracture. Lancet 1:687\u2013690","journal-title":"Lancet"},{"key":"1286_CR34","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00223-004-0084-2","volume":"76","author":"Rejnmark","year":"2005","unstructured":"Rejnmark L, Vestergaard P, Mosekilde L (2005) Reduced fracture risk in users of thiazide diuretics. Calcif Tissue Int 76:167\u2013175","journal-title":"Calcif Tissue Int"},{"key":"1286_CR35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1359\/JBMR.051003","volume":"21","author":"Rejnmark","year":"2006","unstructured":"Rejnmark L, Vestergaard P, Heickendorff L et al (2006) Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res 21:163\u2013170","journal-title":"J Bone Miner Res"},{"key":"1286_CR36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2796.2005.01585.x","volume":"259","author":"Rejnmark","year":"2006","unstructured":"Rejnmark L, Vestergaard P, Mosekilde L (2006) Fracture risk in patients treated with loop diuretics. J Intern Med 259:117\u2013124","journal-title":"J Intern Med"},{"key":"1286_CR37","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1517\/14740338.2013.770469","volume":"12","author":"Rendell","year":"2013","unstructured":"Rendell M, Akturk HK, Tella SH (2013) Glargine safety, diabetes and cancer. Expert Opin Drug Saf 12:247\u2013263","journal-title":"Expert Opin Drug Saf"},{"key":"1286_CR38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00198-011-1574-5","volume":"23","author":"Roux","year":"2012","unstructured":"Roux C, Goldstein JL, Zhou X et al (2012) Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporos Int 23:277\u2013284","journal-title":"Osteoporos Int"},{"key":"1286_CR39","doi-asserted-by":"crossref","first-page":"476","DOI":"10.7326\/0003-4819-139-6-200309160-00010","volume":"139","author":"Schoofs","year":"2003","unstructured":"Schoofs MW, Klift M van der, Hofman A et al (2003) Thiazide diuretics and the risk for hip fracture. Ann Intern Med 139:476\u2013482","journal-title":"Ann Intern Med"},{"key":"1286_CR40","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1210\/jc.2005-2226","volume":"91","author":"Schwartz","year":"2006","unstructured":"Schwartz AV, Sellmeyer DE, Vittinghoff E et al (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349\u20133354","journal-title":"J Clin Endocrinol Metab"},{"key":"1286_CR41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1503\/cmaj.071330","volume":"179","author":"Targownik","year":"2008","unstructured":"Targownik LE, Lix LM, Metge CJ et al (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179:319\u2013326","journal-title":"CMAJ"},{"key":"1286_CR42","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1053\/j.gastro.2009.11.014","volume":"138","author":"Targownik","year":"2010","unstructured":"Targownik LE, Lix LM, Leung S, Leslie WD (2010) Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138:896\u2013904","journal-title":"Gastroenterology"},{"key":"1286_CR43","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00223-006-0021-7","volume":"79","author":"Vestergaard","year":"2006","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79:76\u201383","journal-title":"Calcif Tissue Int"},{"key":"1286_CR44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1254\/jphs.92.43","volume":"92","author":"Yamaura","year":"2003","unstructured":"Yamaura K, Yonekawa T, Nakamura T et al (2003) The histamine H2-receptor antagonist, cimetidine, inhibits the articular osteopenia in rats with adjuvant-induced arthritis by suppressing the osteoclast differentiation induced by histamine. J Pharmacol Sci 92:43\u201349","journal-title":"J Pharmacol Sci"},{"key":"1286_CR45","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","volume":"296","author":"Yang","year":"2006","unstructured":"Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947\u20132953","journal-title":"JAMA"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-013-1286-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-013-1286-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-013-1286-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:36:17Z","timestamp":1559061377000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-013-1286-7"}},"subtitle":["Protonenpumpenhemmer, Glitazone, Diuretika"],"short-title":[],"issued":{"date-parts":[[2014,4,13]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["1286"],"URL":"https:\/\/doi.org\/10.1007\/s00393-013-1286-7","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,13]]}}}